DACIKAST is an NS5A inhibitor that prevents hepatitis C virus (HCV) replication and slows disease progression.
Recommended for:
Adults diagnosed with chronic HCV infection
Combination therapy with sofosbuvir (± ribavirin)
Patients with or without compensated cirrhosis
All HCV genotypes (1 through 6)
Treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents
Take once daily, orally, with or without food, as part of a combination antiviral regimen (commonly with sofosbuvir). Duration of therapy depends on HCV genotype and liver status.
Known hypersensitivity to daclatasvir or its excipients
Pregnancy and breastfeeding
Use in children is not recommended
Side effects:
Fatigue, headache
Nausea, insomnia
Anaemia (especially with ribavirin)
